A carregar...
Safety and Tolerability of PCSK9 Inhibitors: Current Insights
The current era of preventive cardiology continues to emphasize on low-density lipoprotein cholesterol (LDL-C) reduction to alleviate the burden of atherosclerotic cardiovascular disease (ASCVD). In this regard, the pharmacological inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9)...
Na minha lista:
| Publicado no: | Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7737942/ https://ncbi.nlm.nih.gov/pubmed/33335431 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CPAA.S288831 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|